




PHARMACEUTICAL 2023

Karyopharm Therapeutics Inc.
Rank 341 of 446





PHARMACEUTICAL 2023

Karyopharm Therapeutics Inc.
Rank 341 of 446



The relative strengths and weaknesses of Karyopharm Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Karyopharm Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is -53%, being 96% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	350,162
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	65,908
Liabilities, Non-Current	6,097
Other Assets	6,871
Other Compr. Net Income	-829
Other Expenses	5,582
Other Liabilities	302,823
Other Net Income	-22,720
Other Revenues	157,074
Property and Equipment	1,139
Research and Development	148,662
Selling, General and Administrative Expense	145,401

Output Variable	Value in 1000 USD
Assets	358,172
Liabilities	374,828
Expenses	299,645
Revenues	157,074
Stockholders Equity	-16,656
Net Income	-165,291
Comprehensive Net Income	-165,706
Economic Capital Ratio	-53%